Welcome to our dedicated page for Galera Therapeutics SEC filings (Ticker: GRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galera Therapeutics, Inc. (GRTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Galera’s clinical-stage biopharmaceutical activities, financial condition, strategic decisions, and changes in trading status.
Galera’s periodic reports, such as Forms 10-K and 10-Q referenced in its press releases, discuss its focus on developing novel, proprietary therapeutics related to radiotherapy and cancer, including historical work on superoxide dismutase mimetics and more recent emphasis on a pan-nitric oxide synthase inhibitor in advanced breast cancer. These filings typically describe research and development expenses, general and administrative costs, net losses, cash and cash equivalents, and risk factors associated with funding needs, regulatory uncertainty, and potential cessation of operations.
Current reports on Form 8-K are especially important for tracking material events. For example, an October 2025 Form 8-K details an Asset Purchase and Sale Agreement under which Biossil Inc. agreed to acquire all of Galera’s right, title, and interest in assets related to avasopasem, rucosopasem, and other dismutase mimetic assets, and to assume related obligations under a royalty agreement, in exchange for an upfront payment and potential future milestone and contingent value right payments. Another Form 8-K notes that Galera’s common stock trades on the OTCQB Market under the symbol GRTX.
Earlier disclosures referenced in company communications include information about the Board’s approval of a Plan of Liquidation and Dissolution, adoption of a limited duration stockholder rights agreement, workforce reductions, and the engagement of financial advisors to review strategic alternatives. Together, these filings document Galera’s transition from a Nasdaq-listed clinical-stage oncology company through strategic review, proposed dissolution, acquisition of Nova Pharmaceuticals, and sale of key assets.
On Stock Titan, AI-powered tools can help interpret Galera’s filings by summarizing complex sections of Forms 10-K and 10-Q, highlighting key terms in material agreements disclosed on Form 8-K, and organizing information about trading status and corporate actions. This allows readers to quickly understand how regulatory filings relate to Galera’s evolving business and the GRTX stock.
Galera Therapeutics entered a definitive all-stock merger agreement with Obsidian Therapeutics, under which both companies will become wholly owned subsidiaries of a new parent that plans to operate as Obsidian Therapeutics and list on Nasdaq as “OBX.” At closing, based on current estimates, Obsidian equityholders are expected to own about 53.2% of the combined company, existing Galera holders about 1.8%, and investors in a concurrent private placement about 45.0%, reflecting valuations of approximately $413.5 million for Obsidian and $13.8 million for Galera, assuming Galera net cash of $1.8 million.
The deal is supported by an oversubscribed $350.0 million PIPE financing in Galera Series C non-voting convertible preferred stock, which will convert into Galera common and then into parent common stock at the merger. The combined company’s cash, including PIPE proceeds, is expected to fund operations into the second half of 2028, covering key milestones for Obsidian’s lead TIL cell therapy OBX‑115, including Phase 1 NSCLC data in the first half of 2027 and topline melanoma data by year-end 2027.
Galera stockholders will also receive one contingent value right per Galera share, giving them rights to net proceeds from any monetization of Galera’s legacy small-molecule assets, including tilarganine and supportive-care candidates, and to future milestone payments under Galera’s October 2025 asset sale to Biossil.ai. The merger is subject to customary closing conditions, including stockholder approvals, effectiveness of a Form S‑4 registration statement, receipt of approximately $350 million in PIPE proceeds, continued Galera trading on the OTCQB and Nasdaq listing approval for the new parent’s stock.
Galera Therapeutics, Inc. has filed a preliminary proxy statement for a combined 2025 and 2026 Annual Meeting to be held virtually on May 8, 2026. The filing discloses management proposals including director elections, ratification of KPMG LLP as auditor, advisory say-on-pay items, and three charter amendments: (1) increase authorized common stock to 400,000,000 shares, (2) permit stockholder action by written consent, and (3) authorize a reverse stock split at a ratio between 1:75 and 1:200 to be effected at the Board’s discretion. The filing states 160,429,783 shares outstanding as of the April 10, 2026 record date and discloses 39,373,206 shares reserved for issuance and 10,599,059 options outstanding.
Nancy T. Chang, a director of Galera Therapeutics, Inc., filed a Schedule 13D reporting beneficial ownership of 8,921,543 shares of common stock, representing about 5.9% of the company. Her position reflects shares bought in a December 2024 private placement, equity received in Galera’s acquisition of Nova Pharmaceuticals, and stock options.
In the December 2024 private placement, she purchased 7,644,932 shares at $0.0654 per share using personal funds, as part of a broader 44,111,260-share and pre-funded warrant financing. She also received Series B non-voting convertible preferred stock in the Nova merger, part of which was later mandatorily converted into 1,180,611 common shares. Her remaining stake includes 661.309 Series B preferred shares and an option for 96,000 common shares vesting over 36 months.
Galera Therapeutics director-associated IRA converted preferred stock into common shares through a company-initiated action. On April 7, 2026, 5,336.87 shares of Series B Non-Voting Convertible Preferred Stock indirectly held for Michael Friedman were mandatorily converted into 5,336,870 shares of Common Stock based on a 1,000:1 Conversion Ratio. The securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA, which now holds 5,336,870 common shares indirectly following the conversion.
Galera Therapeutics director and 10% owner Nancy T. Chang converted preferred stock into common shares. On a board-initiated partial mandatory conversion effective April 7, 2026, 1,180.611 shares of Series B Non-Voting Convertible Preferred Stock were converted into 1,180,611 shares of common stock at a stated conversion price of $0.00 per share.
After the conversion, Chang directly held 8,825,543 shares of common stock and 661.309 shares of Series B Preferred Stock. This was a derivative conversion, not an open-market purchase or sale, and followed a February 12, 2026 amendment allowing the board to elect mandatory conversions based on a 1,000-to-1 conversion ratio.
Galera Therapeutics, Inc. converted 76,479.175 shares of its Series B Non-Voting Convertible Preferred Stock into 76,479,164 shares of common stock on April 7, 2026, under the existing Certificate of Designation. Fractional common shares will be settled in cash based on the trading value at the conversion date.
After this partial mandatory conversion, 42,839.11 shares of Series B Preferred Stock remain outstanding. On April 8, 2026, affiliates of Ikarian Capital, LLC exercised pre-funded warrants for 8,488,229 common shares at an exercise price of $0.001 per share, providing approximately $8,488.23 to the company, with warrants for an additional 14,552,811 common shares still outstanding.
Galera Therapeutics, Inc. has scheduled its Combined 2025 and 2026 Annual Meeting of Stockholders for May 8, 2026. Because this date is more than 60 days after the prior Annual Meeting held on February 24, 2025, the company is updating key stockholder proposal and nomination deadlines.
Stockholders seeking to nominate directors or present other business under the company’s Amended and Restated Bylaws must deliver notice to the secretary at the principal executive office by April 13, 2026. To use the universal proxy rules under Rule 14a-19, stockholders soliciting proxies for alternative nominees must also provide the required notice by April 13, 2026. The company will treat stockholder proposals received on or before April 13, 2026 as received a reasonable time before it prints and mails proxy materials for possible inclusion under Rule 14a-8.
Galera Therapeutics, Inc. files its annual report describing a major strategic shift and current risks. The company sold its historical radiotherapy assets, including avasopasem and rucosopasem, to Biossil for a $3.5 million upfront payment plus up to $105.0 million in contingent value rights and milestone opportunities, and Biossil assumed Galera’s royalty obligations to Blackstone.
Galera acquired Nova Pharmaceuticals, adding a pan-NOS inhibitor program now focused on treating aggressive breast cancers such as metaplastic and triple-negative disease. A Phase 1/2 investigator-sponsored trial is underway, funded by an NIH grant, with additional U.S. cancer centers participating. An I-SPY 2 collaboration for triple-negative breast cancer is being planned, contingent on new capital.
As of December 31, 2025, Galera had 3 employees and reported that its cash balance is anticipated to fund operations through the first quarter of 2027. Despite a $151.0 million non-cash gain from extinguishing the Blackstone royalty liability and net income of $149.0 million in 2025, the company carries an accumulated deficit of $307.3 million and warns that its ability to continue as a going concern depends on raising additional funding while it relies heavily on a single, unapproved product candidate.
Galera Therapeutics, Inc. amended the terms of its Series B Non-Voting Convertible Preferred Stock. The company’s board of directors now has the sole discretion to elect to convert, in whole or in part, outstanding shares of this preferred stock into common stock, using the Conversion Ratio defined in the original certificate of designation.
This change was approved both by the board and by unanimous written consent of the holders of the Series B Non-Voting Preferred Stock, and the amendment was filed with the Secretary of State of Delaware as a Certificate of Amendment.
Galera Therapeutics, Inc. entered into a letter agreement with Joel Sussman, its Chief Accounting Officer, Treasurer, Secretary, and a named executive officer, establishing retention-based cash bonus payments tied to timely completion and filing of certain company reporting obligations.
Under the agreement, Mr. Sussman may receive up to $250,000 in total retention bonuses. Any retention bonuses paid will reduce, on a dollar-for-dollar basis, any severance otherwise due to him under his existing employment agreement. If his employment is involuntarily terminated without cause, or he resigns for good reason, any unpaid retention bonus will be paid regardless of whether the original conditions are met.